Literature DB >> 22202026

Cancer stem cells and resistance to chemo and radio therapy.

Babar Malik1, Daotai Nie.   

Abstract

Cancer stem cells (CSCs, or tumor initiating cells) are responsible for tumor initiation. If cancer treatment kills most of cancer cells in the stage of transit amplifying and differentiation without killing the stem cells, the surviving CSCs will eventually lead to recurrence of tumors. Studies have suggested that CSCs may be the primary mediators of resistance to chemo- and radio-therapy, leading to failure in cancer therapy. Numerous targets are being investigated for their potential involvement in the self-renewal and chemo- and radio-resistance of cancer cells. However, despite the intensive efforts invested into characterizing the role of cancer stem cells, there is a sense of uncertainty regarding the identity and number of these cells as well as the implications in cancer treatment. In this review, we will discuss the identification of CSCs by cell surface markers, the biology of CSCs, and the role of CSCs in resistance to radio- and chemo-therapy. This review will discuss the advances in targeting CSCs to improve the efficacy of chemo- and radio-therapy.

Entities:  

Mesh:

Year:  2012        PMID: 22202026     DOI: 10.2741/531

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  32 in total

1.  Break the loop, escape the cycle?

Authors:  Renée van Amerongen; Anton Berns
Journal:  EMBO J       Date:  2013-06-07       Impact factor: 11.598

Review 2.  Small cell lung cancer: will recent progress lead to improved outcomes?

Authors:  M Catherine Pietanza; Lauren Averett Byers; John D Minna; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

3.  Hyperbaric oxygen and cancer: more complex than we expected.

Authors:  Liu Wenwu; Sun Xuejun; Tao Hengyi; Liu Kan
Journal:  Target Oncol       Date:  2013-01-24       Impact factor: 4.493

Review 4.  Chemical Proteomic Approaches Targeting Cancer Stem Cells: A Review of Current Literature.

Authors:  Hye Jin Jung
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

Review 5.  Targeting Notch signalling pathway of cancer stem cells.

Authors:  Vandana Venkatesh; Raghu Nataraj; Gopenath S Thangaraj; Murugesan Karthikeyan; Ashok Gnanasekaran; Shanmukhappa B Kaginelli; Gobianand Kuppanna; Chandrashekrappa Gowdru Kallappa; Kanthesh M Basalingappa
Journal:  Stem Cell Investig       Date:  2018-03-12

Review 6.  Role of OCT4 in cancer stem-like cells and chemotherapy resistance.

Authors:  Ismail S Mohiuddin; Sung-Jen Wei; Min H Kang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-03-21       Impact factor: 5.187

7.  PLK1 inhibition down-regulates polycomb group protein BMI1 via modulation of the miR-200c/141 cluster.

Authors:  Manjari Dimri; Joon-Ho Cho; Mingu Kang; Goberdhan P Dimri
Journal:  J Biol Chem       Date:  2014-12-12       Impact factor: 5.157

8.  Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.

Authors:  Dong-Rong Yang; Xian-Fan Ding; Jie Luo; Yu-Xi Shan; Ronghao Wang; Shin-Jen Lin; Gonghui Li; Chiung-Kuei Huang; Jin Zhu; Yuhchyau Chen; Soo Ok Lee; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

Review 9.  JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells.

Authors:  Chifumi Kitanaka; Atsushi Sato; Masashi Okada
Journal:  Genes Cancer       Date:  2013-09

10.  Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.

Authors:  Zhiyong Yang; Ning Zhao; Jing Cui; Heshui Wu; Jiongxin Xiong; Tao Peng
Journal:  Cell Oncol (Dordr)       Date:  2019-11-12       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.